AAPL327.74+1.15 (+0.35%) ▲|ABBV256.10+2.72 (+1.07%) ▲|ABT99.67-1.99 (-1.96%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.84+4.12 (+3.20%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.41+28.51 (+2.49%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|AAPL327.74+1.15 (+0.35%) ▲|ABBV256.10+2.72 (+1.07%) ▲|ABT99.67-1.99 (-1.96%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.84+4.12 (+3.20%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.41+28.51 (+2.49%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|
24.5 C
New York
Tuesday, July 21, 2026

Tag: disease progression

newssourceFORcompanyinformationcontent1releasesmarket

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV

New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan 
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/...

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones.

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDisease progression

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers